喘息薬の世界市場レポート 2024

喘息薬の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には5.5%の年間複合成長率（CAGR）で300億米ドルに成長すると予想されています。予測期間中に予測される成長は、大気汚染レベルの上昇、高齢化人口の増加、ヘルスケア意識の高まり、個別化医療への傾向、バイオ医薬品の革新などの要因に起因すると考えられます。予測期間中に予想される主な動向には、低分子治療の開発、在宅喘息ケアの拡大、バイオマーカーに基づく治療の使用、重度喘息の治療アプローチの進歩、喘息調査における共同努力が含まれます。

喘息の有病率のエスカレートは、近い将来、喘息薬市場の拡大の原動力となると予想されます。喘息は気道の炎症と狭窄を引き起こす持続的な病気であり、新しい喘息薬の探求が急増しています。この急増は、喘息の症例が増加していることへの対応です。 2023年5月に米国疾病管理予防センターが報告したように、米国の喘息有病者数は2021年に2,496万人に急増し、3,517人が死亡しました。その結果、喘息疾患の急増により革新的な医薬品の開発が促進され、喘息薬市場の成長が促進されます。

呼吸器疾患の有病率の増加により、喘息薬市場は上昇する傾向にあります。肺、気管支、気管、鼻道などの呼吸器系に影響を及ぼす疾患を含む呼吸器疾患が、喘息薬の需要を押し上げています。これらの症状、特に喘息などの慢性炎症性疾患がさらに蔓延するにつれて、効果的な治療法の必要性が高まっています。たとえば、2021年2月のNCDアライアンスのデータでは、肺がんが世界のがん関連死亡の主な原因であることが強調され、新たな感染者が220万人、死亡者が180万人と予測されています。したがって、呼吸器疾患の蔓延が喘息薬市場を前進させることになるでしょう。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の喘息薬市場、喘息タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• アレルギー
• 非アレルギー性
• 世界の喘息薬市場、喘息トリガータイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 成人発症喘息
• 小児喘息
• 咳喘息
• 運動誘発性喘息
• 職業性喘息
• 夜間喘息
• ステロイド抵抗性喘息
• 世界の喘息薬市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 予防
• 治療
• 世界の喘息薬市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 気管支拡張薬
• モノクローナル抗体
• 抗炎症薬
• 配合剤
• 世界の喘息薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 喘息患者
• 慢性閉塞性肺疾患（COPD）患者

第7章 地域および国の分析

• 世界の喘息薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の喘息薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 喘息薬市場の競合情勢
• 喘息薬市場の企業プロファイル
  • Pfizer Inc.
  • Roche Holding AG
  • Merck &Co. Inc.
  • Bayer AG
  • Sanofi SA

第31章 その他の大手および革新的な企業

• AstraZeneca PLC.
• GlaxoSmithKline PLC.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Novartis International AG
• Mylan NV
• Koninklijke Philips NV
• Cipla Limited
• Chiesi Farmaceutici SpA
• Sun Pharmaceutical Industries Limited
• Hikma Pharmaceuticals
• Mundipharma International Limited
• Lupin Limited
• Glenmark Pharmaceuticals Limited
• Hetero Drugs Limited

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Asthma is a chronic respiratory condition characterized by inflammation and constriction of the airways, resulting in difficulty breathing. This condition is triggered by factors such as allergens, leading to airway narrowing and excess mucus production. Asthma drugs play a vital role in managing symptoms associated with asthma.

Asthma can be categorized into allergic and non-allergic types. Allergic asthma involves airway constriction triggered by exposure to allergens, leading to respiratory difficulties. Various triggers for asthma include adult-onset asthma, child-onset asthma, cough-induced asthma, exercise-induced asthma, occupational asthma, nocturnal asthma, and steroid-resistant asthma. Asthma drugs are classified into bronchodilators, monoclonal antibodies, anti-inflammatory drugs, and combination drugs, catering to the needs of asthma and COPD patients.

The asthma drugs market research report is one of a series of new reports from The Business Research Company that provides asthma drugs market statistics, including the asthma drugs industry global market size, regional shares, competitors with a chronic kidney disease market share, detailed asthma drugs market segments, asthma drugs market trends, and opportunities, and any further data you may need to thrive in the asthma drugs industry. This asthma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The asthma drugs market size has grown strongly in recent years. It will grow from $23.05 billion in 2023 to $24.25 billion in 2024 at a compound annual growth rate (CAGR) of 5.2%. The growth observed in the historical period can be attributed to various factors, including environmental influences, a rise in respiratory disorders, shifts in lifestyle, and the development of healthcare infrastructure.

The asthma drugs market size is expected to see strong growth in the next few years. It will grow to $30 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The projected growth in the forecast period can be attributed to factors such as increasing air pollution levels, a growing aging population, rising healthcare awareness, the trend toward personalized medicine, and innovations in biopharmaceuticals. Key trends anticipated in the forecast period include the development of small molecule therapies, the expansion of home-based asthma care, the use of biomarker-guided therapies, advancements in therapeutic approaches for severe asthma, and collaborative efforts in asthma research.

The escalating prevalence of asthmatic conditions is anticipated to be a driving force behind the expansion of the asthma drug market in the foreseeable future. Asthma, a persistent ailment causing inflammation and constriction of airways, has led to an upsurge in the quest for novel asthma drugs. This surge is a response to the mounting cases of asthma. As reported by the US Centers for Disease Control and Prevention in May 2023, the prevalence of asthma in the US surged to 24.96 million in 2021, contributing to 3,517 deaths. Consequently, the surge in asthmatic disorders fosters the development of innovative drugs, thereby propelling growth within the asthma drug market.

The increasing prevalence of respiratory ailments is poised to elevate the asthma drug market. Respiratory diseases, encompassing afflictions affecting the respiratory system, including the lungs, bronchi, trachea, and nasal passages, are driving the demand for asthma drugs. As these conditions, especially chronic inflammatory diseases such as asthma, become more pervasive, the necessity for efficient therapeutic remedies intensifies. For instance, data from the NCD Alliance in February 2021 highlighted lung cancer as the leading cause of global cancer-related fatalities, projecting 2.2 million new cases and 1.8 million deaths. Hence, the burgeoning prevalence of respiratory illnesses is set to propel the asthma drug market forward.

Innovative product development stands as a significant trend gaining traction within the asthma drug market. Major players within this sector are strategically focused on creating novel solutions to maintain their market position. An illustration of this trend is evident in the collaboration between Amgen, a US-based biopharmaceutical company, and AstraZeneca, a UK-based biopharmaceutical company, resulting in the FDA approval of Tezpire, an injectable drug engineered to alleviate asthma symptoms. Tezpire's mechanism of action involves curbing inflammation linked to asthma attacks, exhibiting potential benefits for individuals with severe asthma, including those previously lacking effective treatment options. As the first biologic to consistently reduce asthma-related exacerbations in Phase 2 and 3 clinical trials, the approval of Tezpire promises greater therapeutic advantages, aligning with the escalating instances of asthma cases.

Prominent entities within the asthma drug market are ardently committed to product innovation, exemplified by the introduction of indacaterol plus mometasone. This innovative fixed-dose combination medication aims to enhance the management of uncontrolled asthma by improving lung function, bolstering symptom control, and reducing exacerbations. Notably, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, unveiled the novel Indacaterol plus Mometasone drug, marketed as Indamet, in June 2022. This pioneering drug, the first of its kind in India, caters to adults and adolescents (aged 12 and above) grappling with uncontrolled asthma. Positioned as a world-class yet affordable treatment option, Indamet offers promising relief for individuals coping with unmanaged asthma, reinforcing the ongoing emphasis on innovative advancements within the asthma drug market.

In March 2022, Sandoz, a German pharmaceutical company, successfully acquired Coalesce Product Development Limited for an undisclosed sum. This strategic acquisition aligns with Sandoz's goal of expanding its respiratory division's portfolio and solidifying its global leadership in respiratory products. Through this transaction, Sandoz gains valuable assets and enhanced capabilities in medical and drug-device development, particularly in the respiratory and complex generics markets. The acquisition positions Sandoz to better serve patients with respiratory diseases, including asthma and COPD, by offering affordable and high-quality drug-device combination products, such as inhalers. Coalesce Product Development Limited, based in the UK, is a company specializing in the development of drug delivery devices, boasting a diverse portfolio that includes pressurized metered-dose inhalers, breath-actuated inhalers, pre-metered dry powder inhalers, and more.

Major companies operating in the asthma drugs market report are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC., GlaxoSmithKline PLC., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Novartis International AG, Mylan N.V., Koninklijke Philips N.V, Cipla Limited, Chiesi Farmaceutici S.p.A., Sun Pharmaceutical Industries Limited, Hikma Pharmaceuticals, Mundipharma International Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Alembic Pharmaceuticals Limited, Sunovion Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Beximco Pharmaceuticals Ltd., Innoviva Inc., Vectura Group, Circassia Group PLC, Pari Medical Holding GmbH, Pulmatrix Inc., Atopix Therapeutics Limited

North America was the largest region in the asthma drugs market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the asthma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The asthma drugs market consists of sales of drugs such as bronchodilators (beta-2 agonists), monoclonal antibodies (omalizumab, mepolizumab), and anti-inflammatory drugs (budesonide, ciclesonide), used for the treatment of asthma in patients of all ages. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Asthma Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on asthma drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for asthma drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The asthma drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type Of Asthma: Allergic; Non-Allergic
• 2) By Asthma Trigger Type: Adult-Onset Asthma; Child-Onset Asthma; Cough-Induced Asthma; Exercise-Induced Asthma; Occupational Asthma; Nocturnal Asthma; Steroid-Resistant Asthma
• 3) By Therapy: Preventive; Curative
• 4) By Drug Class: Bronchodilators; Monoclonal Antibodies; Anti-Inflammatory Drugs; Combination Drugs
• 5) By End-User: Asthma Patients; COPD Patients
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Asthma Drugs Market Characteristics

3. Asthma Drugs Market Trends And Strategies

4. Asthma Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Asthma Drugs Market Size and Growth

• 5.1. Global Asthma Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Asthma Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Asthma Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Asthma Drugs Market Segmentation

• 6.1. Global Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Allergic
• Non-Allergic
• 6.2. Global Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Adult-Onset Asthma
• Child-Onset Asthma
• Cough-Induced Asthma
• Exercise-Induced Asthma
• Occupational Asthma
• Nocturnal Asthma
• Steroid-Resistant Asthma
• 6.3. Global Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Preventive
• Curative
• 6.4. Global Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Bronchodilators
• Monoclonal Antibodies
• Anti-Inflammatory Drugs
• Combination Drugs
• 6.5. Global Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Asthma Patients
• Chronic Obstructive Pulmonary Disease (COPD) Patients

7. Asthma Drugs Market Regional And Country Analysis

• 7.1. Global Asthma Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Asthma Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Asthma Drugs Market

• 8.1. Asia-Pacific Asthma Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Asthma Drugs Market

• 9.1. China Asthma Drugs Market Overview
• 9.2. China Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Asthma Drugs Market

• 10.1. India Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Asthma Drugs Market

• 11.1. Japan Asthma Drugs Market Overview
• 11.2. Japan Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Asthma Drugs Market

• 12.1. Australia Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Asthma Drugs Market

• 13.1. Indonesia Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Asthma Drugs Market

• 14.1. South Korea Asthma Drugs Market Overview
• 14.2. South Korea Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Asthma Drugs Market

• 15.1. Western Europe Asthma Drugs Market Overview
• 15.2. Western Europe Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Asthma Drugs Market

• 16.1. UK Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Asthma Drugs Market

• 17.1. Germany Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Asthma Drugs Market

• 18.1. France Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Asthma Drugs Market

• 19.1. Italy Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Asthma Drugs Market

• 20.1. Spain Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Asthma Drugs Market

• 21.1. Eastern Europe Asthma Drugs Market Overview
• 21.2. Eastern Europe Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Asthma Drugs Market

• 22.1. Russia Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Asthma Drugs Market

• 23.1. North America Asthma Drugs Market Overview
• 23.2. North America Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Asthma Drugs Market

• 24.1. USA Asthma Drugs Market Overview
• 24.2. USA Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Asthma Drugs Market

• 25.1. Canada Asthma Drugs Market Overview
• 25.2. Canada Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Asthma Drugs Market

• 26.1. South America Asthma Drugs Market Overview
• 26.2. South America Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Asthma Drugs Market

• 27.1. Brazil Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Asthma Drugs Market

• 28.1. Middle East Asthma Drugs Market Overview
• 28.2. Middle East Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Asthma Drugs Market

• 29.1. Africa Asthma Drugs Market Overview
• 29.2. Africa Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Asthma Drugs Market Competitive Landscape And Company Profiles

• 30.1. Asthma Drugs Market Competitive Landscape
• 30.2. Asthma Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Roche Holding AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co. Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bayer AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Sanofi S.A.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Asthma Drugs Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC.
• 31.2. GlaxoSmithKline PLC.
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Novartis International AG
• 31.6. Mylan N.V.
• 31.7. Koninklijke Philips N.V
• 31.8. Cipla Limited
• 31.9. Chiesi Farmaceutici S.p.A.
• 31.10. Sun Pharmaceutical Industries Limited
• 31.11. Hikma Pharmaceuticals
• 31.12. Mundipharma International Limited
• 31.13. Lupin Limited
• 31.14. Glenmark Pharmaceuticals Limited
• 31.15. Hetero Drugs Limited

32. Global Asthma Drugs Market Competitive Benchmarking

33. Global Asthma Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Asthma Drugs Market

35. Asthma Drugs Market Future Outlook and Potential Analysis

• 35.1 Asthma Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Asthma Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Asthma Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer